The Angiotensin Type 1 Receptor Activates Extracellula G Protein-Dependent and -Independent Pathways in Ca Langendorff-Perfused Hearts

Basic and Clinical Pharmacology and Toxicology 100, 289-295

DOI: 10.1111/j.1742-7843.2007.00063.x

Citation Report

#	Article	IF	CITATIONS
1	S100A4 is upregulated in injured myocardium and promotes growth and survival of cardiac myocytes. Cardiovascular Research, 2007, 75, 40-50.	1.8	141
2	Differential Extracellular Signal-Regulated Kinases 1 and 2 Activation by the Angiotensin Type 1 Receptor Supports Distinct Phenotypes of Cardiac Myocytes. Basic and Clinical Pharmacology and Toxicology, 2007, 100, 296-301.	1.2	73
3	Effect of Dopamine Receptor 1 on Apoptosis of Cultured Neonatal Rat Cardiomyocytes in Simulated Ischaemia/Reperfusion. Basic and Clinical Pharmacology and Toxicology, 2008, 102, 329-336.	1.2	34
4	βâ€∎rrestins and heterotrimeric Gâ€proteins: collaborators and competitors in signal transduction. British Journal of Pharmacology, 2008, 153, S298-309.	2.7	141
5	The human angiotensin AT1 receptor supports G protein-independent extracellular signal-regulated kinase 1/2 activation and cellular proliferation. European Journal of Pharmacology, 2008, 590, 255-263.	1.7	25
6	Pharmacologic Perspectives of Functional Selectivity by the Angiotensin II Type 1 Receptor. Trends in Cardiovascular Medicine, 2008, 18, 305-312.	2.3	22
7	A perspective on more effective GPCR-targeted drug discovery efforts. Expert Opinion on Drug Discovery, 2008, 3, 375-389.	2.5	9
8	Lack of Evidence for AT1R/B2R Heterodimerization in COS-7, HEK293, and NIH3T3 Cells. Journal of Biological Chemistry, 2009, 284, 1831-1839.	1.6	49
9	Molecular determinants of angiotensin II type 1 receptor functional selectivity. Journal of Molecular and Cellular Cardiology, 2009, 46, 15-24.	0.9	51
10	Physiologic and cardiac roles of β-arrestins. Journal of Molecular and Cellular Cardiology, 2009, 46, 300-308.	0.9	50
11	Functional interactions between 7TM receptors in the Renin-Angiotensin System—Dimerization or crosstalk?. Molecular and Cellular Endocrinology, 2009, 302, 203-212.	1.6	35
12	Therapeutic Potential of Functional Selectivity in the Treatment of Heart Failure. Trends in Cardiovascular Medicine, 2010, 20, 221-227.	2.3	5
13	βâ€Arrestin 1 and 2 stabilize the angiotensin II type I receptor in distinct highâ€affinity conformations. British Journal of Pharmacology, 2010, 161, 150-161.	2.7	25
14	Biased Signaling of the Angiotensin II Type 1 Receptor Can Be Mediated through Distinct Mechanisms. PLoS ONE, 2010, 5, e14135.	1.1	34
15	Quantitative Phosphoproteomics Dissection of Seven-transmembrane Receptor Signaling Using Full and Biased Agonists. Molecular and Cellular Proteomics, 2010, 9, 1540-1553.	2.5	135
16	Functional Selectivity in Adrenergic and Angiotensin Signaling Systems. Molecular Pharmacology, 2010, 78, 983-992.	1.0	71
17	The impact of ANG II and IV on INS-1 cells and on blood glucose and plasma insulin. Journal of Receptor and Signal Transduction Research, 2010, 30, 234-245.	1.3	7
18	Selectively Engaging Î ² -Arrestins at the Angiotensin II Type 1 Receptor Reduces Blood Pressure and Increases Cardiac Performance. Journal of Pharmacology and Experimental Therapeutics, 2010, 335, 572, 570	1.3	330

CITATION REPORT

#	Article	IF	CITATIONS
19	Therapeutic potential of Î ² -arrestin- and G protein-biased agonists. Trends in Molecular Medicine, 2011, 17, 126-139.	3.5	469
20	β-Arrestin: A signaling molecule and potential therapeutic target for heart failure. Journal of Molecular and Cellular Cardiology, 2011, 51, 534-541.	0.9	79
21	Angiotensin II type 1 receptor signalling regulates microRNA differentially in cardiac fibroblasts and myocytes. British Journal of Pharmacology, 2011, 164, 394-404.	2.7	56
22	Cell-specific detection of microRNA expression during cardiomyogenesis by combined in situ hybridization and immunohistochemistry. Journal of Molecular Histology, 2011, 42, 289-299.	1.0	37
23	Biased Ligands for Better Cardiovascular Drugs. Circulation Research, 2011, 109, 205-216.	2.0	122
24	Functional Relevance of Biased Signaling at the Angiotensin II Type 1 Receptor. Endocrine, Metabolic and Immune Disorders - Drug Targets, 2011, 11, 99-111.	0.6	16
25	Deciphering biased-agonism complexity reveals a new active AT1 receptor entity. Nature Chemical Biology, 2012, 8, 622-630.	3.9	182
26	TRV120027, a Novel β-Arrestin Biased Ligand at the Angiotensin II Type I Receptor, Unloads the Heart and Maintains Renal Function When Added to Furosemide in Experimental Heart Failure. Circulation: Heart Failure, 2012, 5, 627-634.	1.6	114
27	Exogenous hydrogen sulfide attenuates diabetic myocardial injury through cardiac mitochondrial protection. Molecular and Cellular Biochemistry, 2012, 371, 187-198.	1.4	34
28	Functionally Selective AT1Receptor Activation Reduces Ischemia Reperfusion Injury. Cellular Physiology and Biochemistry, 2012, 30, 642-652.	1.1	16
29	Conducting the G-protein coupled receptor (GPCR) signaling symphony in cardiovascular diseases: New therapeutic approaches. Drug Discovery Today: Disease Models, 2012, 9, e85-e90.	1.2	6
30	GPCR biased ligands as novel heart failure therapeutics. Trends in Cardiovascular Medicine, 2013, 23, 242-249.	2.3	38
31	Cloning and Characterization of the <i><scp>GNA</scp>11</i> Promoter and its Regulation by Early Growth Response 1. Basic and Clinical Pharmacology and Toxicology, 2013, 113, 316-324.	1.2	3
32	Mechanosensing and Regulation of Cardiac Function. Journal of Clinical & Experimental Cardiology, 2014, 05, 314.	0.0	16
33	Quantifying Biased β-Arrestin Signaling. Handbook of Experimental Pharmacology, 2014, 219, 57-83.	0.9	13
34	Calcium Sensing Receptor Promotes Cardiac Fibroblast Proliferation and Extracellular Matrix Secretion. Cellular Physiology and Biochemistry, 2014, 33, 557-568.	1.1	37
35	Arrestins - Pharmacology and Therapeutic Potential. Handbook of Experimental Pharmacology, 2014, , .	0.9	12
36	Biased Ligand Modulation of Seven Transmembrane Receptors (7TMRs): Functional Implications for Drug Discovery. Journal of Medicinal Chemistry, 2014, 57, 6887-6896.	2.9	40

#	Article	IF	Citations
37	Proximal tubule NHE3 activity is inhibited by beta-arrestin-biased angiotensin II type 1 receptor signaling. American Journal of Physiology - Cell Physiology, 2015, 309, C541-C550.	2.1	15
38	Biased Agonism of the Angiotensin II Type I Receptor. International Heart Journal, 2015, 56, 485-488.	0.5	27
39	Heart Failure Therapeutics on theÂBasisÂofÂaÂBiased Ligand of theÂAngiotensin-2 TypeÂ1ÂReceptor. JACC: Heart Failure, 2015, 3, 193-201.	1.9	68
40	Sodium hydrosulfide attenuates hyperhomocysteinemia rat myocardial injury through cardiac mitochondrial protection. Molecular and Cellular Biochemistry, 2015, 399, 189-200.	1.4	19
41	International Union of Basic and Clinical Pharmacology. XCIX. Angiotensin Receptors: Interpreters of Pathophysiological Angiotensinergic Stimuli. Pharmacological Reviews, 2015, 67, 754-819.	7.1	245
42	Micro <scp>RNA</scp> â€155 attenuates activation of hepatic stellate cell by simultaneously preventing <scp>EMT</scp> process and <scp>ERK</scp> 1 signalling pathway. Liver International, 2015, 35, 1234-1243.	1.9	43
43	Exogenous H2S modulates mitochondrial fusion–fission to inhibit vascular smooth muscle cell proliferation in a hyperglycemic state. Cell and Bioscience, 2016, 6, 36.	2.1	29
44	β-Arrestin-biased AT1R stimulation promotes extracellular matrix synthesis in renal fibrosis. American Journal of Physiology - Renal Physiology, 2017, 313, F1-F8.	1.3	19
45	Ang-(1-7) is an endogenous \hat{l}^2 -arrestin-biased agonist of the AT1 receptor with protective action in cardiac hypertrophy. Scientific Reports, 2017, 7, 11903.	1.6	82
46	Biased for benefit: Stimulating the world's most popular drug targets with more nuance. Nature Medicine, 2017, 23, 649-651.	15.2	1
47	Novel mechanisms of G-protein-coupled receptors functions: AT1 angiotensin receptor acts as a signaling hub and focal point of receptor cross-talk. Best Practice and Research in Clinical Endocrinology and Metabolism, 2018, 32, 69-82.	2.2	43
48	[Sar1, Ile4, Ile8]â€angiotensin II Potentiates Insulin Receptor Signalling and Glycogen Synthesis in Hepatocytes. Basic and Clinical Pharmacology and Toxicology, 2018, 122, 460-469.	1.2	2
49	β-Arrestin Based Receptor Signaling Paradigms: Potential Therapeutic Targets for Complex Age-Related Disorders. Frontiers in Pharmacology, 2018, 9, 1369.	1.6	75
51	Designer Approaches for G Protein–Coupled Receptor Modulation for Cardiovascular Disease. JACC Basic To Translational Science, 2018, 3, 550-562.	1.9	23
52	The Role of β-Arrestin Proteins in Organization of Signaling and Regulation of the AT1 Angiotensin Receptor. Frontiers in Endocrinology, 2019, 10, 519.	1.5	34
53	β-Arrestin-biased AT1R stimulation promotes cell survival during acute cardiac injury. American Journal of Physiology - Heart and Circulatory Physiology, 2012, 303, H1001-H1010.	1.5	105
54	Predicting Kinase Activity in Angiotensin Receptor Phosphoproteomes Based on Sequence-Motifs and Interactions. PLoS ONE, 2014, 9, e94672.	1.1	7
55	Biased G Protein-Coupled Receptor Signaling: New Player in Modulating Physiology and Pathology. Biomolecules and Therapeutics, 2017, 25, 12-25.	1.1	87

CITATION REPORT

#	Article	IF	CITATIONS
56	Functional Selectivity at Non-Opioid Peptide Receptors. , 2009, , 267-281.		0
57	Inositol 1,4,5-trisphosphate receptor - reactive oxygen signaling domain regulates excitation-contraction coupling in atrial myocytes. Journal of Molecular and Cellular Cardiology, 2022, 163, 147-155.	0.9	4
59	Spermine ameliorates ischemia/reperfusion injury in cardiomyocytes via regulation of autophagy. American Journal of Translational Research (discontinued), 2016, 8, 3976-3985.	0.0	15
60	β-Arrestin as a Therapeutic Target in Heart Failure. Cardiology in Review, 2021, 29, 223-229.	0.6	8
65	Loss of biased signaling at a G protein-coupled receptor in overexpressed systems. PLoS ONE, 2023, 18, e0283477.	1.1	7
66	Interactions between AT1R and GRKs: the determinants for activation of signaling pathways involved in blood pressure regulation. Molecular Biology Reports, 2024, 51, .	1.0	0

CITATION REPORT